Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIX NASDAQ:BRNS NASDAQ:MDXH NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$2.92$6.95$2.90▼$32.55$1.58M-1.32629,900 shs7.99 million shsBRNSBarinthus Biotherapeutics$0.60$0.66$0.51▼$1.83$24.59M-0.4144,518 shs17,143 shsMDXHMDxHealth$0.41$0.56$0.40▼$5.33$20.30M1.43538,084 shs389,406 shsSYRESpyre Therapeutics$102.13$85.42$14.51▼$105.09$8.98B3.021.18 million shs811,705 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%-34.38%-48.95%-61.48%-90.00%BRNSBarinthus Biotherapeutics0.00%-1.31%-14.00%-4.44%-66.37%MDXHMDxHealth0.00%-3.03%-3.94%-79.90%-83.53%SYRESpyre Therapeutics0.00%+1.90%+16.20%+42.04%+474.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$2.92$6.95$2.90▼$32.55$1.58M-1.32629,900 shs7.99 million shsBRNSBarinthus Biotherapeutics$0.60$0.66$0.51▼$1.83$24.59M-0.4144,518 shs17,143 shsMDXHMDxHealth$0.41$0.56$0.40▼$5.33$20.30M1.43538,084 shs389,406 shsSYRESpyre Therapeutics$102.13$85.42$14.51▼$105.09$8.98B3.021.18 million shs811,705 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%-34.38%-48.95%-61.48%-90.00%BRNSBarinthus Biotherapeutics0.00%-1.31%-14.00%-4.44%-66.37%MDXHMDxHealth0.00%-3.03%-3.94%-79.90%-83.53%SYRESpyre Therapeutics0.00%+1.90%+16.20%+42.04%+474.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 2.00Hold$42.001,338.36% UpsideBRNSBarinthus Biotherapeutics 2.00Hold$4.00564.45% UpsideMDXHMDxHealth 2.40Hold$3.50753.66% UpsideSYRESpyre Therapeutics 2.92Moderate Buy$101.42-0.70% DownsideCurrent Analyst Ratings BreakdownLatest AMIX, BRNS, SYRE, and MDXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026SYRESpyre Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$84.00 ➝ $120.007/10/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/23/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/23/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $135.006/16/2026SYRESpyre Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$100.006/15/2026SYRESpyre Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $112.006/15/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/4/2026SYRESpyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.006/3/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$10.85 per shareN/ABRNSBarinthus Biotherapeutics$14.97M1.64N/AN/A$1.82 per share0.33MDXHMDxHealth$107.88M0.19N/AN/A($0.24) per share-1.71SYRESpyre Therapeutics$890K10,091.36N/AN/A$7.21 per share14.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$16.72M-$74.58N/AN/AN/AN/A-239.36%-192.46%8/12/2026 (Estimated)BRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%8/6/2026 (Estimated)MDXHMDxHealth-$33.52M-$0.65N/AN/AN/A-29.90%N/A-22.51%8/13/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest AMIX, BRNS, SYRE, and MDXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MDXHMDxHealth-$0.1934N/AN/AN/A$26.14 millionN/A8/12/2026Q1 2027AMIXAutonomix Medical-$6.4050N/AN/AN/AN/AN/A8/6/2026Q2 2026BRNSBarinthus Biotherapeutics-$0.28N/AN/AN/AN/AN/A8/4/2026Q2 2026SYRESpyre Therapeutics-$0.71N/AN/AN/AN/AN/A5/14/2026Q1 2026MDXHMDxHealth-$0.1447-$0.19-$0.0454-$0.17$30.89 million$23.90 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A4.454.45BRNSBarinthus BiotherapeuticsN/A6.056.05MDXHMDxHealthN/A1.631.46SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%BRNSBarinthus Biotherapeutics25.20%MDXHMDxHealthN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical6.20%BRNSBarinthus Biotherapeutics8.50%MDXHMDxHealth1.70%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical1540,000509,000N/ABRNSBarinthus Biotherapeutics10740.85 million37.38 millionN/AMDXHMDxHealth30049.50 million48.66 millionNot OptionableSYRESpyre Therapeutics7387.94 million74.14 millionOptionableAMIX, BRNS, SYRE, and MDXH HeadlinesRecent News About These CompaniesSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Moderate Buy" from Brokerages1 hour ago | marketbeat.comSpyre Therapeutics, Inc. $SYRE Stake Decreased by Commodore Capital LP2 hours ago | marketbeat.comSpyre Therapeutics, Inc. $SYRE is Affinity Asset Advisors LLC's 6th Largest PositionJuly 25 at 3:12 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading 5.7% Higher - Should You Buy?July 17, 2026 | marketbeat.comWhy Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 10.35%July 14, 2026 | aaii.comASpyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year High After Analyst UpgradeJuly 14, 2026 | marketbeat.comEmerald Advisers LLC Sells 22,744 Shares of Spyre Therapeutics, Inc. $SYREJuly 14, 2026 | marketbeat.comSpyre Therapeutics Stock Dividends | NASDAQ:SYRE | BenzingaJuly 13, 2026 | benzinga.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Mizuho Analyst SaysJuly 13, 2026 | marketbeat.comCandriam S.C.A. Buys 184,748 Shares of Spyre Therapeutics, Inc. $SYREJuly 12, 2026 | marketbeat.comJefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)July 6, 2026 | theglobeandmail.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $658,050.00 in StockJuly 3, 2026 | insidertrades.comSpyre Therapeutics Announces Grants of Inducement AwardsJuly 2, 2026 | globenewswire.comSpyre Therapeutics, Inc. $SYRE Stock Holdings Decreased by Pictet Asset Management Holding SAJuly 2, 2026 | marketbeat.comSpyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting DataJune 30, 2026 | seekingalpha.comIs SYRE Stock a Buy Now or a Wait-and-See Biotech Story TodayJune 29, 2026 | zacks.comSpyre Therapeutics Stock Outlook Hinges on 2026 Study CatalystsJune 29, 2026 | zacks.comSYRE and Spyre Ride New IBD Trends in Biotech Drug DesignJune 29, 2026 | zacks.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,306,950.00 in StockJune 27, 2026 | insidertrades.comSpyre Therapeutics: A Platform Where The Combination Strategy Is The Real AssetJune 26, 2026 | seekingalpha.comBiotech ETF Index Surges 10% After RebalanceJune 25, 2026 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, BRNS, SYRE, and MDXH Company DescriptionsAutonomix Medical NASDAQ:AMIX$2.92 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.09 +0.17 (+5.89%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Barinthus Biotherapeutics NASDAQ:BRNS$0.60 0.00 (0.00%) Closing price 07/24/2026 03:55 PM EasternExtended Trading$0.62 +0.02 (+3.49%) As of 07/24/2026 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.MDxHealth NASDAQ:MDXH$0.41 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.41 +0.00 (+0.73%) As of 07/24/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Spyre Therapeutics NASDAQ:SYRE$102.13 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$103.00 +0.87 (+0.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
